Stocktoria
Alpha Cognition Inc. ACOG
Alpha Cognition Inc. (ACOG) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $10.2M at a -202.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.876 |
| Retained earnings / assets | -1.218 |
| EBIT / assets | -0.284 |
| Equity / liabilities | 3.635 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ACOG | Alpha Cognition Inc. | 2/9 | 3.69 | — | — |
| TSHA | Taysha Gene Therapies, Inc. | 4/9 | -0.53 | — | — |
| CRIS | CURIS INC | 2/9 | — | — | -13.4% |
| CRBU | Caribou Biosciences, Inc. | 2/9 | -9.88 | — | — |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
| FATE | FATE THERAPEUTICS INC | 1/9 | -13.3 | — | -51.2% |
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
About Alpha Cognition Inc.
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
FAQ
Is ACOG financially healthy?
Alpha Cognition Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ACOG pay a dividend?
No, Alpha Cognition Inc. does not currently pay a dividend.
How profitable is ACOG?
In FY2025, Alpha Cognition Inc. had a net margin of -202.2% and a return on equity of -33.1%.
What is the analyst price target for ACOG?
The average Wall-Street price target for Alpha Cognition Inc. is $14.67, about 63.9% above the recent price, from 3 analysts.
Is ACOG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Alpha Cognition Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.